Loading...
Docoh
Log in Free sign up

Dynavax Technologies (DVAX)

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Company profile

Ticker
DVAX
Exchange
NASDAQ
Website
www.dynavax.com
CEO
Ryan Spencer
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
SEC CIK
0001029142
Corporate docs
Subsidiaries
Dynavax GmbH ...
IRS number
330728374

DVAX stock data

News

From Benzinga Pro
Dynavax Technologies Q2 EPS $0.87 Beats $0.22 Estimate, Sales $256.46M Beat $150.99M Estimate
4 Aug 22
Dynavax Technologies (NASDAQ:DVAX) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.22 by 295.45 percent. This is a 1350 percent increase over earnings of $0.06 per share
Dynavax Technologies: Q2 Earnings Insights
4 Aug 22
Dynavax Technologies (NASDAQ:DVAX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Earnings Scheduled For August 4, 2022
4 Aug 22
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
12 Health Care Stocks Moving In Monday's After-Market Session
25 Jul 22
110 Biggest Movers From Friday
16 May 22

Press releases

From Benzinga Pro
Thinking about buying stock in AN2 Therapeutics, AMTD IDEA Group, Dynavax Technologies, Yelp, or Honest Company?
5 Aug 22
NEW YORK, Aug. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANTX, AMTD, DVAX, YELP, and HNST.
Dynavax Reports Second Quarter 2022 Financial Results
4 Aug 22
Q2 2022 total revenue of $256.5 million, up 386% from $52.8 million for Q2 2021HEPLISAV-B® vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021CpG 1018® adjuvant net
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva's Inactivated COVID-19 Vaccine
1 Aug 22
Saint-Herblain (France), August 1, 2022 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreement (APA)1 with the European
Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022
21 Jul 22
European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 Vaccine
20 Jul 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
12 Aug 22
31 Dec 22

Financial summary

Financial statements Chart DVAX financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Financial data from company earnings reports.

Recent insider trades

DVAX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Aug 22 Ryan Spencer Common Stock Sell Dispose S No No 16.9157 14,921 252.4K 144,513
9 Aug 22 David F Novack Common Stock Sell Dispose S No No 16.9157 26,250 444.04K 53,213
9 Aug 22 Janssen Robert Common Stock Sell Dispose S No No 16.9157 7,938 134.28K 35,519
8 Aug 22 Cano Francis Common Stock Sell Dispose S No No 17.17 15,000 257.55K 20,834
8 Aug 22 Cano Francis Common Stock Option exercise Acquire M No No 4.97 15,000 74.55K 35,834
8 Aug 22 Cano Francis Stock Option Common Stock Option exercise Dispose M No No 4.97 15,000 74.55K 0
8 Aug 22 Ryan Spencer Common Stock Option exercise Acquire M No No 0 29,663 0 159,434
8 Aug 22 Ryan Spencer RSU Common Stock Option exercise Acquire M No No 0 29,663 0 9,887
8 Aug 22 David F Novack Common Stock Option exercise Acquire M No No 0 26,250 0 79,463
8 Aug 22 David F Novack RSU Common Stock Option exercise Dispose M No No 0 26,250 0 8,750
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

DVAX institutional ownership history Ownership history
86.1% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 203 205 -1.0%
Opened positions 22 45 -51.1%
Closed positions 24 30 -20.0%
Increased positions 73 55 +32.7%
Reduced positions 63 60 +5.0%
13F shares Current Prev Q Change
Total value 1.1B 1.36B -19.3%
Total shares 108.87M 104.35M +4.3%
Total puts 1.23M 1.19M +3.2%
Total calls 1.27M 1.3M -2.4%
Total put/call ratio 1.0 0.9 +5.7%
Largest owners Shares Value Change
FHI Federated Hermes 16.54M $179.27M +2.0%
STT State Street 8.5M $92.13M +36.1%
Bain Capital Life Sciences Investors 8.42M $91.22M 0.0%
BLK Blackrock 7.79M $84.49M -0.9%
Bain Capital Life Sciences Fund 7.63M $0 0.0%
Chicago Capital 5.86M $63.48M +2.1%
Vanguard 5.84M $63.34M -1.0%
Partner Fund Management 3.81M $41.25M 0.0%
Fisher Asset Management 3.51M $38.06M -2.6%
Blair William & Co 2.55M $27.66M +13.8%
Largest transactions Shares Bought/sold Change
STT State Street 8.5M +2.25M +36.1%
Edmond De Rothschild Holding 2.45M +1.98M +430.0%
Norges Bank 0 -750K EXIT
D. E. Shaw & Co. 1.4M -679.31K -32.6%
Renaissance Technologies 621.65K +374.1K +151.1%
Two Sigma Investments 1.37M +350.81K +34.5%
GS Goldman Sachs 2.18M +342.36K +18.6%
FHI Federated Hermes 16.54M +330K +2.0%
BAC Bank Of America 643.16K +320.4K +99.3%
Voloridge Investment Management 280.17K -311.99K -52.7%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • AMGEN • VBI Vaccines • Celgene • Idera Pharmaceuticals • Roche • Novavax • Agenus • Novartis • Sanofi

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: adware, alleviate, attack, awaiting, belonging, branch, broadly, code, compromise, compromised, conflict, credential, distributor, EC, email, error, extortion, Farma, frequency, hardware, irreparable, Italy, macroeconomic, malware, media, misconduct, Persero, physical, PT, ransomware, ready, Russia, server, software, stuffing, threat, Ukraine, unwilling
Removed: Bavarian, CHMP, commence, HBV, headwind, Inducement, Israel, lifted, likelihood, Nordic, paused, pose, shift, therapy
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
3 Nov 21
10-Q
2021 Q2
Quarterly report
4 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
25 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
Current reports
View all
8-K
Dynavax Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Departure of Directors or Certain Officers
25 May 22
8-K
Dynavax Reports First Quarter 2022 Financial Results
5 May 22
8-K
Entry into a Material Definitive Agreement
16 Mar 22
8-K
Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance
27 Feb 22
8-K
Departure of Directors or Certain Officers
14 Dec 21
8-K
Dynavax Reports Third Quarter 2021 Financial Results
4 Nov 21
8-K
Departure of Directors or Certain Officers
21 Oct 21
8-K
Dynavax Announces Second Quarter 2021 Financial Results
4 Aug 21
8-K
Entry into a Material Definitive Agreement
7 Jul 21
Registration and prospectus
View all
S-8
Registration of securities for employees
2 Jun 22
S-8
Registration of securities for employees
4 Aug 21
S-8
Registration of securities for employees
25 Feb 21
S-3ASR
Automatic shelf registration
6 Aug 20
S-8
Registration of securities for employees
6 Aug 20
S-3ASR
Automatic shelf registration
2 Jul 20
424B5
Prospectus supplement for primary offering
22 May 20
424B5
Prospectus supplement for primary offering
21 May 20
POS AM
Prospectus update (post-effective amendment)
11 Mar 20
POSASR
Automatic shelf registration (post-effective amendment)
11 Feb 20
Proxies
View all
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
16 Apr 21
DEF 14A
Definitive proxy
16 Apr 21
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEF 14A
Definitive proxy
17 Apr 20
PRE 14A
Preliminary proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
23 May 19
DEF 14A
Definitive proxy
22 Apr 19
Other
View all
CT ORDER
Confidential treatment order
15 Jul 21
CT ORDER
Confidential treatment order
3 Mar 21
CT ORDER
Confidential treatment order
30 Sep 20
EFFECT
Notice of effectiveness
1 May 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
16 Apr 19
CT ORDER
Confidential treatment order
15 Apr 18
CORRESP
Correspondence with SEC
6 Jul 17
UPLOAD
Letter from SEC
6 Jul 17
UPLOAD
Letter from SEC
5 Jul 17
Ownership
View all
4
DYNAVAX TECHNOLOGIES / Robert Janssen ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / David F Novack ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / Ryan Spencer ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / FRANCIS CANO ownership change
10 Aug 22
4
DYNAVAX TECHNOLOGIES / Justin Burgess ownership change
8 Aug 22
4
DYNAVAX TECHNOLOGIES / Robert Janssen ownership change
8 Aug 22
4
DYNAVAX TECHNOLOGIES / David F Novack ownership change
8 Aug 22
SC 13G
DYNAVAX TECHNOLOGIES / BlackRock ownership change
9 Jun 22
4
DYNAVAX TECHNOLOGIES / Andrew A. F. Hack ownership change
27 May 22
4
DYNAVAX TECHNOLOGIES / Scott Dunseth Myers ownership change
27 May 22

Patents

View all
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
3 Feb 22
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Utility
IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
7 Oct 21
The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
21 Sep 21
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
Utility
Combination of a PD-1 Antagonist and CPG-C Type Oligonucleotide for Treating Cancer
1 Jul 21
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (T1119) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
24 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.

Transcripts

View all
2022 Q2
Earnings call transcript
5 Aug 22
2022 Q1
Earnings call transcript
6 May 22
2021 Q4
Earnings call transcript
28 Feb 22
2021 Q3
Earnings call transcript
5 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
7 May 21
2020 Q4
Earnings call transcript
26 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
7 May 20

Reddit threads

View all